GLP-1-related research spans approved prescription medicines and investigational compounds. Semaglutide, tirzepatide and retatrutide differ in receptor targets and regulatory status; they should not be treated as interchangeable products.
This overview explains the terminology and evidence boundaries. It does not recommend products for weight loss, performance or self-treatment.
GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone involved in:
GLP-1 receptor agonist medicines act at the GLP-1 receptor. Effects, approved uses and risks depend on the particular medicine and formulation. NIDDK explains GLP-1 medicines.
Clinical claims require evidence for the exact intervention, including:
Popularity or receptor activity alone does not establish product safety, effectiveness or suitability.
These names describe different compounds, not equivalent retail treatment options:
Approval applies to a specific drug product and indication—not every material sharing an ingredient name. See FDA information on tirzepatide approval and FDA concerns about unapproved GLP-1 products and retatrutide.
GLP-1 receptor signaling involves several physiological processes. These are mechanistic observations, not guaranteed benefits from research materials:
For a fuller explanation, read how GLP-1 medications work. Mechanism alone does not establish a particular product’s clinical efficacy.
GenLab Meds listings are intended for laboratory and scientific research. That intended-use statement does not establish regulatory approval, safety or clinical equivalence:
Keep the distinction between scientific evidence, approved medicines and research materials clear. Treatment decisions require a licensed healthcare professional and authorized options.
For laboratory-material questions, review stated specifications and available analytical documentation. Do not infer safety or suitability from promotional language or a research-use label.
